European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер unknown
Опубликована: Дек. 7, 2024
Journal of Nuclear Medicine, Год журнала: 2024, Номер unknown, С. jnumed.124.268509 - jnumed.124.268509
Опубликована: Ноя. 7, 2024
The diagnosis and surveillance of clear cell renal carcinoma (ccRCC) remains a clinical challenge. high specific expression the cluster differentiation 70 (CD70) in ccRCC makes it potential diagnostic therapeutic target.
Язык: Английский
Процитировано
6
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер unknown
Опубликована: Сен. 9, 2024
Язык: Английский
Процитировано
4
Nature Reviews Urology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 14, 2024
Язык: Английский
Процитировано
4
Journal of Nuclear Medicine, Год журнала: 2024, Номер unknown, С. jnumed.124.267527 - jnumed.124.267527
Опубликована: Ноя. 14, 2024
This study aimed to investigate the diagnostic efficacy of [
Язык: Английский
Процитировано
3
Molecular Pharmaceutics, Год журнала: 2025, Номер unknown
Опубликована: Фев. 6, 2025
Prostate-specific membrane antigen (PSMA) is a potential target for the diagnosis and treatment of angiogenesis in clear cell renal carcinoma (ccRCC). We aimed to investigate degree PSMA signal variability ccRCC assess its correlation with neovascularization tumor microenvironment. included 120 patients suspected tumors who underwent [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) scan before surgery this retrospective study, including 98 ccRCC, 17 non-ccRCC, 5 benign diseases. compared maximum standard uptake value (SUVmax) tumor-to-liver ratio (TLR) primary lesions different groups analyzed diagnostic efficacy imaging ccRCC. The coefficient variation (CV) SUVmax, which reflects intertumor heterogeneity, volume (VR), intratumor were obtained from PET imaging. between immunohistiochemical (IHC) staining, microvessel density (MVD), serum vascular endothelial growth factor (VEGF) inter- heterogeneity metastases. In our showed significantly higher SUVmax TLR non-ccRCC diseases (F = 14.48, p < 0.001; F 14.49, 0.001). IHC staining exhibited moderate (r 0.421, 0.021) MVD 0.518, 0.003), but it was not correlated VEGF -0.003, 0.989). had 0.448, 0.013) 0.345, 0.020). Serum weak 0.338, 0.145). Based on correlation, SUVmax-to-angiogenesis model validated. mean values lesions, bone metastases, thrombi 16.13, 18.69, 6.02, respectively. CV 58.5%, 55.9%, 80.6%. VR 0.33, 0.46, 0.75, 81.8%, 41.3%, 26.7%. corresponding metastases 0.52, 0.011; r 0.87, 0.024). lesion localized advanced no significant difference (p 0.251), while 0.049). conclusion, PET/CT an effective molecular tool assessing differentiating MVD, VEGF. than that Primary highest high invasive behavior. by has positive effect metastasis.
Язык: Английский
Процитировано
0
Journal of Nuclear Medicine, Год журнала: 2025, Номер unknown, С. jnumed.124.268835 - jnumed.124.268835
Опубликована: Фев. 27, 2025
CD70 is an emerging biomarker for both solid tumors and hematologic malignancies, highlighting the urgent need a molecular imaging tracer capable of visualizing with favorable pharmacokinetics. Methods: ABDB6 was prepared by fusing albumin-binding domain ABD035 CD70-targeting single-domain antibody RCCB6, which we previously reported. The resulting then conjugated to bifunctional chelator p-SCN-NOTA labeled 64Cu produce [64Cu]Cu-NOTA-ABDB6. Flow cytometry used screen 6 lymphoma cell lines varying expression levels. Cell uptake in vivo immuno-PET studies were conducted fully evaluate pharmacokinetic properties tumor-targeting efficacy An blocking study performed validate targeting specificity [64Cu]Cu-NOTA-ABDB6, followed immunohistochemistry fluorescent immunostaining correlate expression. Results: labeling achieved high radiochemical yield specific activity. Significant observed 5 (TMD8, HBL1, OCI-LY10, LCL-EBV, type III latency Burkitt [BL] cells) but not I BL cells, served as negative control. [64Cu]Cu-NOTA-ABDB6 exhibited good affinity protein at nanomolar level (inhibitory concentration 50%, 91.57 nM) binding human CD70. Immuno-PET demonstrated excellent tumor retention various CD70-positive models BL, LCL-EBV), highest values recorded 24.67 ± 1.36, 18.02 4.29, 14.68 1.20 percentage injected dose per gram tissue (%ID/g) 48 h after injection, respectively. These significantly higher than that CD70-negative tumor, had 3.59 0.28 %ID/g same scanning time point (P < 0.05). In TMD8 group, 5.99 lower control group 0.01). Both biodistribution histology results corroborated these findings. Conclusion: effectively visualized levels different models. Its clinical potential may provide insights into patients.
Язык: Английский
Процитировано
0
Med, Год журнала: 2025, Номер unknown, С. 100671 - 100671
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Journal of Nuclear Medicine, Год журнала: 2025, Номер 66(6), С. 865 - 872
Опубликована: Апрель 30, 2025
CD70 has emerged as a promising biomarker for nasopharyngeal carcinoma (NPC). This study investigated expression patterns in NPC specimens and evaluated the diagnostic potential of CD70-targeted [18F]RCCB6 immuno-PET/CT patients with NPC. Methods: was analyzed 80 archived correlated clinical pathologic features. Using [18F]RCCB6, single-domain antibody-derived tracer specific human CD70, efficacy assessed 25 compared that 18F-FDG PET/CT. Results: positively expressed 72 (90%) specimens, levels strongly Epstein-Barr virus (EBV) titers (rs = 0.437; P < 0.001) N-staging (P 0.006). In all 15 early-stage NPC, achieved 100% detection rate primary tumor 93% (75/81) local lymph node metastasis. uptake well expression. head-to-head comparison, demonstrated higher sensitivity than did detecting metastasis (100% [58/58] vs. 90% [52/58], respectively; 0.031), equivalent abilities lesions most distant metastases (100%). Notably, better evaluation skull-base invasion clear border bone metastases, indicated by its (7.25 5.95; 0.025). Conclusion: is potent provides precise mapping enhances diagnosis primary, metastatic, recurrent NPCs, outperforming metastases.
Язык: Английский
Процитировано
0
Trends in cancer, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
2
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер unknown
Опубликована: Дек. 7, 2024
Процитировано
1